Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1258029

Pharmacogenomics in the prediction of cardiovascular drugs adverse reactions - PGx-CardioDrug


Božina, Tamara; Ganoci, Lana; Vrkić Kirhmajer, Majda; Šimičević, Livija; Mucalo, Iva; Palić, Jozefina; Bićanić, Lucija Ana; Samardžić, Jure
Pharmacogenomics in the prediction of cardiovascular drugs adverse reactions - PGx-CardioDrug // 20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022)
Prag, Češka Republika, 2022. (predavanje, međunarodna recenzija, neobjavljeni rad, znanstveni)


CROSBI ID: 1258029 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Pharmacogenomics in the prediction of cardiovascular drugs adverse reactions - PGx-CardioDrug

Autori
Božina, Tamara ; Ganoci, Lana ; Vrkić Kirhmajer, Majda ; Šimičević, Livija ; Mucalo, Iva ; Palić, Jozefina ; Bićanić, Lucija Ana ; Samardžić, Jure

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, znanstveni

Skup
20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022)

Mjesto i datum
Prag, Češka Republika, 18.09.2022. - 21.09.2022

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
drug safety ; interactions ; multidisciplinary ; pharmacogenetic ; risk factors ; cardiovascular drugs ;
(drug safety ; interactions ; multidisciplinary ; pharmacogenetic ; risk factors ; cardiovascular drugs)

Sažetak
Objective: To investigate the multiple drug-drug- gene interactions and their relevance for predicting cardiovascular drugs' adverse drug reactions (ADRs). Preliminary data from our prospective nested case-control study are presented. Patients and methods: The primary cohort of cardiovascular disease patients is represented by subjects who have a new indication for the administration of direct oral anticoagulants (DOAC: dabigatran etexilate, apixaban, rivaroxaban, edoxaban) ; platelet aggregation inhibitors (PAI: clopidogrel, prasugrel, ticagrelor), HMG-CoA reductase inhibitors (simvastatin, atorvastatin, rosuvastatin). Patients were enrolled during the 16 months. The cases represent subjects that developed ADRs during the follow-up period: bleeding from DOACs and PAIs, myotoxicity and hepatotoxicity from statins, other serious ADRs. Control subjects are recruited from the same cohort, among subjects with no ADRs from the enrolment to at least 3- month follow up. All subjects were genotyped for relevant ADME gene variants: CYP2C9 *2*3, CYP2C19 *2*3*17, CYP2D6 *3*4*5*6*9*10*41 and xN, CYP2J2*7, CES1 (rs2244613, rs8192935), ABCB1 (c.1236C>T, c.2677G>T/A, c.3435C>T, rs4148738), ABCG2 c.421C>A, SLCO1B1 c.521T>C by Real-Time PCR methods, depending on the used therapy, and were monitored for clinical and laboratory parameters. For drug-drug interactions (DDI), The Lexicomp® Clinical Decision Support System was applied. Results: 450 patients were recruited (female=215, male=235). Among them were genotyped according to prescribed drug substrates for CYP2C9 (n=211 ; 47%), CYP2C19 (n=262 ; 58%), CYP3A4 (n=335, 74%), CYP3A5 (n=299, 66%), CYP2D6 (n=101, 22%), CES1 (n=32, 7%), ABCB1 (n=282, 63%), ABCG2 (n=357, 79%), SLCO1B1 (n=214, 48%). ADRs observed were: myotoxicity (n=84, 17%), hepatotoxicity (n=14, 3%), bleeding (n=36, 9%). Potential DDI with increased risk for ADRs were found in group of statins (n=39/182 ; DDI level C=28/182, 15% ; level D=4/182, 2%), DOACs (n=133/135, DDI level C=21%, D=26%) and PAIs (n=68/76, DDI level C=71%, D=2.6%). Conclusion: Our preliminary data point to the drug-drug-gene interactions as an important risk factor for cardiovascular drug adverse reactions.

Izvorni jezik
Engleski

Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)



POVEZANOST RADA


Projekti:
HRZZ-UIP-2020-02-8189 - Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova (PGx-CardioDrug) (Božina, Tamara, HRZZ - 2020-02) ( CroRIS)

Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb


Citiraj ovu publikaciju:

Božina, Tamara; Ganoci, Lana; Vrkić Kirhmajer, Majda; Šimičević, Livija; Mucalo, Iva; Palić, Jozefina; Bićanić, Lucija Ana; Samardžić, Jure
Pharmacogenomics in the prediction of cardiovascular drugs adverse reactions - PGx-CardioDrug // 20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022)
Prag, Češka Republika, 2022. (predavanje, međunarodna recenzija, neobjavljeni rad, znanstveni)
Božina, T., Ganoci, L., Vrkić Kirhmajer, M., Šimičević, L., Mucalo, I., Palić, J., Bićanić, L. & Samardžić, J. (2022) Pharmacogenomics in the prediction of cardiovascular drugs adverse reactions - PGx-CardioDrug. U: 20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022).
@article{article, author = {Bo\v{z}ina, Tamara and Ganoci, Lana and Vrki\'{c} Kirhmajer, Majda and \v{S}imi\v{c}evi\'{c}, Livija and Mucalo, Iva and Pali\'{c}, Jozefina and Bi\'{c}ani\'{c}, Lucija Ana and Samard\v{z}i\'{c}, Jure}, year = {2022}, keywords = {drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, cardiovascular drugs, }, title = {Pharmacogenomics in the prediction of cardiovascular drugs adverse reactions - PGx-CardioDrug}, keyword = {drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, cardiovascular drugs, }, publisherplace = {Prag, \v{C}e\v{s}ka Republika} }
@article{article, author = {Bo\v{z}ina, Tamara and Ganoci, Lana and Vrki\'{c} Kirhmajer, Majda and \v{S}imi\v{c}evi\'{c}, Livija and Mucalo, Iva and Pali\'{c}, Jozefina and Bi\'{c}ani\'{c}, Lucija Ana and Samard\v{z}i\'{c}, Jure}, year = {2022}, keywords = {drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, cardiovascular drugs}, title = {Pharmacogenomics in the prediction of cardiovascular drugs adverse reactions - PGx-CardioDrug}, keyword = {drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, cardiovascular drugs}, publisherplace = {Prag, \v{C}e\v{s}ka Republika} }




Contrast
Increase Font
Decrease Font
Dyslexic Font